Fiche publication
Date publication
août 2025
Journal
Best practice & research. Clinical gastroenterology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent
Tous les auteurs :
Fanizzi F, D'Amico F, Peyrin-Biroulet L, Danese S, Dignass A
Lien Pubmed
Résumé
Inflammatory bowel diseases' traditional management focused primarily on symptom control, often failing to prevent long-term complications such as disease progression, disabilities, hospitalizations and surgeries. The introduction of biologics and small molecules has revolutionized IBD management, enhancing inflammation control. A pivotal advance in this field is represented by the Treat-to-Target approach, which prioritizes the achievement of specific goals like endoscopic remission and biomarker normalization, thus moving beyond symptomatic relief. The STRIDE recommendations have been pivotal in shaping treatment goals, with STRIDE-II advancing this approach by adding timelines to established targets and suggesting histologic remission for UC and transmural healing for CD as supplementary objectives. Future strategies are expected to incorporate these outcomes, aiming for more comprehensive disease control. This review evaluates whether new therapeutic targets are required to address the unmet needs in IBD management and to further improve longterm patient outcomes.
Mots clés
Comprehensive remission, Crohn's disease, Histologic remission, Inflammatory bowel disease, Transmural healing, Treat-to-target strategy, Ulcerative colitis
Référence
Best Pract Res Clin Gastroenterol. 2025 08;77:101990
